Quantum BioPharma (NASDAQ: QNTM) is making strides in the development of LUCID-MS, a proprietary therapy for multiple sclerosis (MS) that aims to directly address myelin loss and neurodegeneration. The company recently announced that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile, with the therapy generally well tolerated, supporting advancement into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis.
The significance of LUCID-MS lies in its differentiated mechanism of action. Unlike existing MS therapies that primarily rely on immune modulation, LUCID-MS aims to prevent and reverse myelin degradation, the underlying pathological process in multiple sclerosis. This approach could represent a first-in-class treatment if proven effective. The company is strengthening operational support for the program through a planned partnership with Allucent and by engaging neurological specialists, as noted in a recent article featuring the company at https://ibn.fm/AUhNl.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on LUCID-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation. Beyond MS, Quantum BioPharma has developed unbuzzd, a product for alcohol misuse, which it spun out to Unbuzzd Wellness Inc. (UWI). Quantum retains a 19.84% ownership stake in UWI and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains full rights to develop similar products for pharmaceutical and medical uses.
The advancement of LUCID-MS into Phase 2 trials marks a critical milestone for Quantum BioPharma and for the MS community. Current treatments for MS often focus on reducing inflammation and modulating the immune system, but they do not directly repair myelin damage. If LUCID-MS can demonstrate efficacy in restoring myelin integrity, it could address a significant unmet need in neurodegenerative disease. The company's progress is being closely watched by investors and researchers alike, as updates are available in the company's newsroom at https://ibn.fm/QNTM.
Forward-looking statements in this article involve risks and uncertainties, including factors beyond management's control. These are detailed in the company's SEC filings, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The company undertakes no duty to update this information unless required by law.
